Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 6:34 PM
Ignite Modification Date:
2025-12-24 @ 6:34 PM
NCT ID:
NCT00850057
Brief Summary:
Primary Objectives
* To determine the safety and maximum tolerated dose (MTD) of Adenovirus-CD154 (Ad-ISF35) when it is injected directly into the lymph nodes of patients with CLL or SLL.
Secondary Objectives
* To determine and monitor clinical and biological responses in patients treated with injections of Ad-ISF35.
* To determine how ISF35 works in CLL/SLL patients' cells.
Study:
NCT00850057
Study Brief:
Protocol Section:
NCT00850057